An overview and discussion of clinical studies with IC14, a chimeric monoclonal antibody directed against human CD14 is presented. These studies include phase 1 trials in: (i) healthy subjects; (ii) healthy subjects challenged with lipopolysaccharide (LPS); and (iii) patients with severe sepsis. The results from clinical studies of IC14 demonstrate this chimeric monoclonal antibody diminishes the systemic inflammatory response directed against LPS and may have potential as a treatment to prevent organ dysfunction in patients with severe sepsis. Furthermore, IC14 treatment was generally well-tolerated in both healthy subjects and severe sepsis patients and did not increase the incidence of secondary infections. Analysis of pharmacology data indicate that higher doses of IC14 are required to saturate membrane-bound CD14 receptors effectively in patients with severe sepsis than in healthy subjects. Finally, the results of non-clinical studies indicate that IC14 should only be administered with concurrent antimicrobial therapy in patients with infection.
References
1.
Yoshimura A. , Lien E., Ingalls RR, Tuomanen E., Dziarski B., Golenbock D.Recognition of Gram-positive bacterial cell wall components by the innate immune system occurs via Toll-like receptor 2. J Immunol1999; 163: 1-5.
2.
Wright SDCD14 and the innate response to bacteria, J Immunol1995; 155: 6—8.
3.
Beutler B., Poltorak A.Sepsis and the evolution of the innate immune response. Crit Care Med2001; 29: S2-6—S6-7.
4.
Pugin J., Heumann D., Tomasz A. et al. CD14 is a pattern recognition receptor. Immunity1994; 1: 509—516.
5.
Takeuchi O., Hoshino K., Kawai T. et al. Differential roles of TLR2 and TLR4 in recognition of Gram-negative and Gram-positive bacterial cell wall components. Immunity1999; 11: 443—451.
6.
Stelter F., Bernheiden M., Menzel R. et al. The molecular basis for therapeutic concepts utilizing CD14 . Prog Clin Biol Res1998; 397: 301—313.
7.
MukaidaN., Ishikawa Y., Ikeda N. et al. Novel insight into molecular mechanism of endotoxin shock: biochemical analysis of LPS receptor signaling in a cell-free system targeting NR-kappa B and regulation of cytokine production/action through beta2 integrin in vivo . J Leukoc Biol1996; 59: 145—151.
8.
Oberholzer A. , Oberholzer C., Moldawer L.Sepsis syndromes: understanding the role of innate and acquired immunity. Shock2001; 16: 83—96.
9.
Schimke J., Mathison J., Morgiewicz J., Ulevitch RJAnti-CD14 mAb treatment provides therapeutic benefit after in vivo exposure to endotoxin. Proc Natl Acad Sci USA1998; 95: 13875—13880.
10.
Leturcq DJ, Moriarty AM, Talbott G. et al. Antibodies against CD 14 protects primates from endotoxin-induced shock. J Clin Invest1996; 98: 1533—1538.
11.
Frevert CW, Matute-Bello G., Skerrett SJ et al. Effect of CD14 blockade in rabbits with Escherichia coli pneumonia and sepsis. J Immunol2000; 164: 5439—5445.
12.
Wenneras C. , Ave P., Huerre M. et al. Blockade of CD14 aggravates experimental shigellosis. J Endotoxin Res2001; 7: 442—446.
13.
Haziot A., Hijiya N., Gangloff SC, Silver J., Goyert SMInduction of a novel mechanism of accelerated bacterial clearance by lipopolysaccharide in CD14-deficient and Toll-like receptor 4-deficient mice. J Immunol2001; 166: 1075—1078.
14.
Opal SM, Palardy JE, Parejo N., JasmanRL. Effect of anti-CD 14 monoclonal antibody on clearance of Escherichia coli bacteremia and endotoxemia. Crit Care Med2003; In press.
15.
Verbon A., Dekkers Pdp, ten Hove T. et al. IC14, and anti-CD 14 antibody, inhibits endotoxin-mediated symptoms and inflammatory responsesin humans. J Immunol2001; 166: 3599—3605.
16.
Axtelle T., Pribble J.IC14, a CD14 specific monoclonal antibody, is a potential treatment for patients with severe sepsis. J Endotoxin Res2001; 7: 310—314
17.
OlszynaDP, Verbon A., Pribble J. et al. IC14, an anti-CD14 antibody, inhibits rises in plasma and cell-associated chemokines in human endotoxemia. Abstract 40th ICAAC Meeting, 2000.
18.
Verbon A., Meijers Jcm, Spek A. et al. IC14, an anti-CD14 antibody, inhibits endotoxin induced fibrinolysis in humans without influencing coagulation activation. Abstract 41st ICAAC Meeting, 2001.
19.
Reinhart K. , Glueck T., Ligtenberg J. et al. Phase 1 study of a recombinant chimeric monoclonal antibody against human CD14 (IC14) in patients with severe sepsis . Crit Care Med2001; 29: A19.
20.
American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference.Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med1992; 20: 864—874.
21.
Burgmann H. , Winkler S., Locker GJ et al. Increased serum concentration of soluble CD14 is a prognostic marker in Gram-positive sepsis. Clin Immunol Immunopathol1996; 80: 307—310.
22.
Endo S., Inada K., Kasai T. et al. Soluble CD14 (sCD14) levels in patients with multiple organ failure (MOF). Res Commun Chem in M PatholPharmacol1994; 84: 17—25.
23.
Haziot A., Rong G., Lin X., Silver J., Goyert S.Recombinant soluble CD14 prevents mortality in mice treated with endotoxin (lipopolysaccharide). J Immunol1995; 154: 6529-6532.
24.
Gluck T., Silver J., Epstein M., Cao P., Farber B., Goyert S.Parameters influencing membrane CD14 expression and soluble CD14 levels in sepsis. Eur J Med Res2001; 6: 351—358.
